Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-03-30 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于举行2022年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding an online performance explanation meeting for the 2022 fiscal year. It references that the 2022 Annual Report has already been disclosed on March 31, 2023, and invites investors to participate in the online meeting on April 7, 2023. The document does not contain the actual annual report or detailed financial data but rather announces the event related to discussing the annual report. The document length is short (892 characters), and it serves as a notice for an investor presentation event rather than the report itself. Therefore, it fits best under Investor Presentation (IP).
2023-03-30 Chinese
未来三年股东分红回报规划（2023年-2025年）
Notice of Dividend Amount Classification · 85% confidence The document is a detailed plan outlining the company's shareholder dividend return policy for the years 2023 to 2025. It discusses principles, conditions, forms, timing, and decision-making procedures related to profit distribution and dividends. It references relevant laws and regulatory guidelines concerning cash dividends and shareholder returns. The content is focused on dividend policy and planning rather than announcing actual dividend amounts or payments. It is not a simple announcement of dividend amounts (which would be DIV), nor is it a report or financial statement. The document is a formal policy plan approved by the board and shareholders, which fits best under the category of Notice of Dividend Amount (DIV) because it relates to dividend distribution plans and policies for shareholders over a multi-year period, providing detailed guidance on dividend returns. Although it is a plan rather than a single dividend announcement, the closest specific category is DIV as it concerns dividend distribution information to shareholders.
2023-03-30 Chinese
2022年度独立董事述职报告（杜兰）
Board/Management Information Classification · 95% confidence The document is titled '2022年度独立董事述职报告' which translates to '2022 Annual Independent Director's Work Report' for Shenzhen BGI Genomics Co., Ltd. It details the independent director's attendance at board meetings, opinions on various board resolutions, committee work, investigations, investor protection efforts, and training during the year 2022. The content is a detailed report on the independent director's duties and activities over the year, which is a form of management or board reporting rather than a financial report or announcement. It is not an annual report (10-K), audit report, earnings release, or any other financial statement. It is also not a short announcement or certification but a substantive report on board/management activities and governance. Therefore, the best fitting category is Board/Management Information (MANG). The document length (5619 characters) supports it being a full report rather than a brief announcement.
2023-03-30 Chinese
关于2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of Shenzhen BGI Genomics Co., Ltd. It details the proposed cash dividend per share, total dividend amount, and related legal and compliance considerations. It includes opinions from the board of directors, independent directors, and the supervisory board, and states that the plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The document length is 2692 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV).
2023-03-30 Chinese
独立董事关于第三届董事会第十六次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of prior approval opinions from independent directors regarding matters to be discussed at the 16th meeting of the third board of directors of Shenzhen BGI Genomics Co., Ltd. It includes opinions on the reappointment of the audit firm for 2023, approval of a donation and related party transaction, and approval of a share repurchase transaction involving a subsidiary. The document is not a full audit report, annual report, or financial statement, but rather a governance-related document expressing independent directors' pre-approval opinions on board meeting agenda items. It relates to board/management information and governance matters rather than financial results or regulatory filings. The document length is short (1181 characters), and it is not an announcement of a report publication but a formal governance opinion. Therefore, the most appropriate classification is Board/Management Information (MANG).
2023-03-30 Chinese
关于控股股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of Shenzhen BGI Genomics Co., Ltd. It details the number of shares pledged, the proportion of shares involved, and the implications of the pledge. There is no financial data, earnings information, or management discussion. The document is a regulatory announcement about a change in shareholding status related to share pledges, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on share pledge details, not a full report or financial statement.
2023-03-17 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.